Some patients with COPD suffer frequent exacerbations (FE). We hypothesised that their systemic proteomic profile would be different from that of non-frequent exacerbators (NFE).
The diagnosis of COPD requires the demonstration of non-fully reversible airflow limitation by spirometry in the appropriate clinical context.
The results of this post hoc analysis support the hypothesis that benralizumab reduces the risk for recurrent COPD exacerbations within the vulnerable 30-to-90–day period in the previously identified responder population.
Patients with COPD can have acute episodes of worsening symptoms, known generically as exacerbations, which are clinically relevant because they involve an acute deterioration of the patient’s health status, worsen the patient’s prognosis, and are the main cause of economic expenditure associated with COPD.
Approximately 25% and 65% of patients hospitalized for an ECOPD die within 1 and 5 years, respectively.
Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. (…)
